The Fifth CIIE is ready to open its door to worldwide participants
SHANGHAI, Sept. 17, 2022 /PRNewswire/ -- Acting as a major platform for international procurement, investment promotion, cultural exchanges and open cooperation, the China International Import Expo (CIIE) has been held for four consecutive years and is widely regarded as an international public good, which in turn is good for economic globalization and multilateral...
CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®
SINGAPORE, Sept. 17, 2022 /PRNewswire/ -- CellResearch Corporation, a Singapore-based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImmune Cell and Gene Therapy. CorLiCyte® is in development for the treatment...
ViVitro Labs Introduces World’s first “Set it and forget it” Heart Valve Durability Tester
New Heart Valve Durability tester with Automatic Dual Control technology debuts at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. "Introducing a New Generation of Durability Testers" VICTORIA, BC, Sept. 16, 2022 /PRNewswire/ -- ViVitro Labs, the industry-leading provider of cardiovascular device test equipment...
New treatment for rare cancer cholangiocarcinoma approved in Australia
Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement PEMAZYRE® (pemigatinib) is available via a co-pay access program in Australia SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- A NEW targeted therapy to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia. PEMAZYRE® (pemigatinib) has...
Sirtex Medical secures positive approval of SIR-Spheres® Y-90 resin microspheres for HCC treatment in Brazil
The Brazilian National Agency of Supplementary Health recommends SIR-Spheres for the treatment of intermediate- and advanced-stage hepatocellular carcinoma WOBURN, Mass., Sept. 15, 2022 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced that the Brazilian National Agency of Supplementary Health (ANS) approved SIR-Spheres® Y-90 resin microspheres for...
Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection
HANGZHOU and SHAOXING, China, Sept. 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection has completed the enrollment of 15 HIV infected patients. The objective of this study (ClinicalTrials.gov Identifier: NCT05129189) is to evaluate...
AXA Hong Kong and HSBC jointly launch HelperShield Insurance
Comprehensive protection for both employers and domestic helpers Extensive coverage and support services to help customers expect the unexpected HONG KONG, Sept. 15, 2022 /PRNewswire/ -- With an increasing market demand for domestic helpers in recent years, AXA Hong Kong ("AXA") and HSBC launch a new insurance plan, "HelperShield Insurance", to offer comprehensive protection to both employers and their...
Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance
SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for bladder cancer diagnosis, has been included in the 2022 edition of the Lecheng Global Specialty Drug Insurance Specialty Drug List....
Austar Lifesciences Announces 2022 Interim Results
Benefiting from the Growth in the Business Segment of Liquid and Bioprocess System and the Increased Capability of Comprehensive Integrated Solutions, its Businesses Grew Steadily Revenue Increased by 29.1% to RMB 1,104 million Operation Highlights (RMB'000) For the six months ended 30 June Growth 2022 2021 ...
BioWorld by Clarivate Adds Laser-focused Preclinical Research News into New Fully Integrated Platform
Migration of BioWorld Science to complete BioWorld brand consolidation LONDON, Sept. 15, 2022 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced BioWorld Science will transition entirely to bioworld.com for an improved experience and expanded news offering. The migration...
